Effects of estrogen replacement therapy on abdominal fat compartments as related to glucose and lipid metabolism in early postmenopausal women
Effects of estrogen replacement therapy on abdominal fat compartments as related to glucose and lipid metabolism in early postmenopausal women
复制标题
DOI：
10.1055/s-2002-35420
复制
发表时间：
2002-10-01
影响因子：
2.2
通讯作者：
Hulthén, UL
中科院分区：
文献类型：
--
作者：
Mattiasson, I;Rendell, M;Hulthén, UL
本文观察了51例52-53岁健康绝经后妇女雌激素替代治疗对脂糖代谢的影响。他们被随机分配到雌二醇2毫克或安慰剂治疗三个月，每天在一个双盲设计。46名妇女在开放设计中继续服用雌二醇9个月，每3个月加用甲羟孕酮10天。在雌激素治疗前和治疗后一年，通过计算机断层扫描估计腹腔内和皮下腹部脂肪，以及盆腔内和皮下盆腔脂肪。治疗3个月和12个月后进行正常血糖高胰岛素钳夹试验、口服葡萄糖耐量试验和血脂分析。雌激素替代疗法减少了体脂量以及腹内和盆腔内脂肪，但对皮下脂肪区隔无影响。低密度脂蛋白胆固醇降低，高密度脂蛋白胆固醇增加，而甘油三酯没有改变一年的雌激素治疗。胰岛素敏感性和糖耐量不受雌激素治疗的影响。在绝经后妇女雌激素治疗一年减少腹腔内和盆腔内脂肪室，但这是不相关的血脂水平的变化。胰岛素敏感性和血浆甘油三酯不受雌激素治疗的影响。
The effects of estrogen replacement therapy on lipid and glucose metabolism as related to abdominal fat distribution were investigated in fifty-one healthy postmenopausal women aged 52-53 years. They were randomized to treatment with either estradiol 2 mg or placebo daily for three months in a double-blind design. Forty-six women continued with estradiol for another nine months in an open design with the addition of medroxyprogesterone for ten days every three months. Intra-abdominal and subcutaneous abdominal fat, and intrapelvic and subcutaneous pelvic fat was estimated by computed tomography before and after one year of estrogen treatment. Euglycemic hyperinsulinemic clamp, oral glucose tolerance test and analyses of blood lipids were performed after 3 and 12 months of treatment. Estrogen replacement therapy decreased body fat mass as well as intra-abdominal and intrapelvic fat, but not the subcutaneous fat compartments. LDL cholesterol decreased and HDL cholesterol increased, whereas triglycerides were not changed by one year of estrogen treatment. Insulin sensitivity and glucose tolerance were not affected by estrogen treatment. In postmenopausal women estrogen treatment for one year decreased intra-abdominal and intrapelvic fat compartments, but this was not related to changes in plasma lipid levels. Insulin sensitivity and plasma triglycerides were not affected by estrogen treatment.